Avrobio (AVRO) has closed its merger with clinical-stage biotechnology company Tectonic Therapeutic, Tectonic said Thursday.
The merged entity will operate as Tectonic Therapeutic, with its shares expected to start trading on the Nasdaq Global Market Friday under the TECX ticker symbol.
Tectonic said it expects its cash, cash equivalents and investments of about $181 million to fund its operation into mid-2027.
Price: 1.4400, Change: +0.04, Percent Change: +2.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments